Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Selinexor- Karyopharm Therapeutics

Next Previous
X
Search
Drug Profile

Selinexor- Karyopharm Therapeutics

Alternative Names: ATG-010; CRM1-nuclear-export-inhibitor; KPT-330; NEXPOVIO; ONO 7705; Selinisso; TP-53; XPOVIO

Latest Information Update: 04 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Karyopharm Therapeutics
  • Developer Antengene Corporation; Cardiff University; Grupo Espanol de Investigacion en Sarcomas; Karyopharm Therapeutics; Menarini; Ono Pharmaceutical; Promedico; University of Texas Southwestern Medical Center
  • Class Acrylamides; Anti-infectives; Antineoplastics; Antivirals; Fluorinated hydrocarbons; Foot disorder therapies; Hydrazines; Pyrazines; Skin disorder therapies; Small molecules; Triazoles
  • Mechanism of Action Exportin 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Multiple myeloma; Myelofibrosis; Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diffuse large B cell lymphoma; Multiple myeloma
  • Phase III Endometrial cancer; Liposarcoma; Myelofibrosis
  • Phase II/III Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase II Colorectal cancer; COVID 2019 infections; Malignant melanoma; Ovarian cancer; Peripheral T-cell lymphoma; Thrombocytopenia; Thymic epithelial tumour; Thymoma; Triple negative breast cancer
  • Phase I/II Gastrointestinal stromal tumours; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours
  • Phase I Liver cancer
  • No development reported B-cell lymphoma; Cervical cancer; Chronic lymphocytic leukaemia; Extranodal NK-T-cell lymphoma; Glioma; HER2 positive breast cancer; Neuroendocrine tumours; Osteosarcoma; Sepsis; Soft tissue sarcoma
  • Discontinued Cutaneous T-cell lymphoma; Diabetic foot ulcer; Gastric cancer; Glioblastoma; Oesophageal cancer; Prostate cancer; Rectal cancer; Richter's syndrome; Small cell lung cancer; Squamous cell cancer

Most Recent Events

  • 23 Aug 2024 Karyopharm Therapeutics terminates a phase II trial in Malignant melanoma (Late-stage disease, Metastatic, Combination Therapy, Second line therapy or greater, First-line therapy, Recurrent) due to lack of sufficient anti-melanoma tumor signal for the combination of selinexor + pembrolizumab (NCT04768881)
  • 06 Aug 2024 Registered for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Malaysia (PO)
  • 31 May 2024 Efficacy and adverse events data from a phase I/II trial in Non-small Cell Lung Cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top